President Trump’s tariffs may impact healthcare companies’ profits, but some like Eli Lilly and Novartis are taking steps to mitigate the damage. Eli Lilly has invested $50 billion in U.S.-based manufacturing, insulating itself from the impact. Novartis plans to invest $23 billion to improve its U.S.-based manufacturing footprint to handle tariffs. Both companies have strong financial results and promising prospects. Eli Lilly has shown innovation and growth, while Novartis has a strong income stock with a forward yield of 3.3%. Despite potential impacts from tariffs, both companies are worth considering for investment.

Read more at Yahoo Finance: Industry-Wide Tariffs Loom Over the Healthcare Sector. Here Are 2 Stocks That Can Weather the Storm.